Umoja Biopharma logo

Umoja Biopharma

umoja-biopharma.com

Umoja Biopharma develops in vivo CAR T cell therapies that generate cancer-fighting T cells directly in a patient’s body. Its therapies are designed to treat cancers while making treatment more accessible by avoiding the multi-week cell manufacturing required for ex vivo CAR T therapies.

Facts

HQ
Seattle, WA 98109
Sectors
Biotechnology Research
Founded
2019
Type
Corporation Seattle business license
Employees
254
Registered name
Umoja Biopharma Inc Seattle business license
Members see funding amounts.
.

Is this your organization? Claim it

BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG

BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.

BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG

Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.

See all 18 stories, episodes and videos about Umoja Biopharma.

People

  • Andy Scharenberg
    Andy Scharenberg Executive Officer, Director, Co-founder & Chief Executive Officer
  • Michael Jensen
    Michael Jensen Co-Founder
  • Nate Hardy Executive, Chief Financial Officer

Online